"Hydroxyurea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
| Descriptor ID |
D006918
|
| MeSH Number(s) |
D02.948.395
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydroxyurea".
Below are MeSH descriptors whose meaning is more specific than "Hydroxyurea".
This graph shows the total number of publications written about "Hydroxyurea" by people in this website by year, and whether "Hydroxyurea" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxyurea" by people in Profiles.
-
Characterising the prevalence of overweight and obese status among adults with sickle cell disease. Br J Haematol. 2023 03; 200(5):633-642.
-
What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease. PLoS One. 2022; 17(11):e0272204.
-
Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. Am J Hematol. 2021 11 01; 96(11):1396-1406.
-
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. Br J Haematol. 2021 11; 195(4):612-620.
-
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2020 04 06; 4:CD012389.
-
Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. Am J Hematol. 2019 12; 94(12):1335-1343.
-
Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children. Pediatrics. 2019 07; 144(1).
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
-
The juxtamembrane linker in neutral sphingomyelinase-2 functions as an intramolecular allosteric switch that activates the enzyme. J Biol Chem. 2019 05 03; 294(18):7488-7502.
-
Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease. Clin Trials. 2019 02; 16(1):20-31.